A smaller Italian study (n = 174) of metastatic melanoma patients ≥ 75 years receiving Anti-PD1 antibodies also showed no association with the number of comorbidities relating to either progression-free or overall survival [27]. The gene discussed is PDCD1; the disease is metastatic melanoma.